ObsEva SA (OBSV)

[Frankestin]

the strong results on the full suppression dose (200 mg) with ABT showed that linzagolix could potentially offer best-in-class efficacy.”
A final marketing authorization decision from the EC is anticipated within two months. The CHMP’s positive opinion follows the recent FDA acceptance for review of the uterine fibroids New Drug Application (NDA) (PDUFA date of September 13, 2022).